Show simple item record

dc.contributor.authorArkenau, H
dc.contributor.authorMartin-Liberal, J
dc.contributor.authorCalvo, E
dc.contributor.authorPenel, N
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorHerbst, R
dc.contributor.authorWalgren, R
dc.contributor.authorWidau, R
dc.contributor.authorMi, G
dc.contributor.authorJin, J
dc.contributor.authorFerry, D
dc.contributor.authorChau, I
dc.date.accessioned2018-07-16T19:23:26Z
dc.date.available2018-07-16T19:23:26Z
dc.date.issued2018-05-31
dc.identifier.citationRamucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). 2018, Oncologisten
dc.identifier.issn1549-490X
dc.identifier.pmid29853658
dc.identifier.doi10.1634/theoncologist.2018-0044
dc.identifier.urihttp://hdl.handle.net/10541/621121
dc.description.abstractRamucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia/b trial.Ramucirumab plus pembrolizumab did not demonstrate an improvement in overall survival when compared with historical controls in biomarker unselected, heavily pretreated patients with advanced or metastatic biliary tract cancer.Patients with programmed death-ligand 1 (PD-L1)-positive tumors had improved overall survival compared with patients with PD-L1-negative disease.
dc.language.isoenen
dc.rightsArchived with thanks to The oncologisten
dc.titleRamucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF).en
dc.typeArticleen
dc.contributor.departmentDrug Development Unit, Sarah Cannon Research Institute UK, Londonen
dc.identifier.journalThe Oncologisten
refterms.dateFOA2018-12-17T15:28:08Z
html.description.abstractRamucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia/b trial.Ramucirumab plus pembrolizumab did not demonstrate an improvement in overall survival when compared with historical controls in biomarker unselected, heavily pretreated patients with advanced or metastatic biliary tract cancer.Patients with programmed death-ligand 1 (PD-L1)-positive tumors had improved overall survival compared with patients with PD-L1-negative disease.


Files in this item

Thumbnail
Name:
The Oncologist-2018-Arkenau-th ...
Size:
683.5Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record